{"id":"abt-slv187","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL4761843","moleculeType":"Unknown","molecularWeight":"704.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug works by blocking soluble epoxide hydrolase, an enzyme that breaks down endogenous anti-inflammatory lipid mediators called EETs. By inhibiting this enzyme, ABT-SLV187 allows EETs to accumulate, which promotes vasodilation, reduces inflammation, and improves endothelial function. This mechanism is being explored for cardiovascular and renal protective effects in various disease states.","oneSentence":"ABT-SLV187 is a selective inhibitor of soluble epoxide hydrolase (sEH) that increases levels of epoxyeicosatrienoic acids (EETs) to reduce inflammation and improve cardiovascular function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:40.927Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT02549092","phase":"PHASE3","title":"A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-26","conditions":"Advanced Parkinson's Disease","enrollment":89},{"nctId":"NCT02082249","phase":"PHASE3","title":"An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-03-10","conditions":"Advanced Parkinson's Disease","enrollment":30},{"nctId":"NCT02799381","phase":"PHASE3","title":"A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-02-09","conditions":"Parkinson's Disease (PD)","enrollment":63},{"nctId":"NCT01960842","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-10","conditions":"Advanced Parkinson's Disease","enrollment":31},{"nctId":"NCT00141518","phase":"PHASE4","title":"Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2006-03","conditions":"Advanced Idiopathic Parkinson's Disease","enrollment":77},{"nctId":"NCT01479127","phase":"PHASE2","title":"Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-10","conditions":"Advanced Parkinson's Disease","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DUOPA™ (carbidopa and levodopa Enteral Suspension)","DUODOPA®","Levodopa-carbidopa intestinal gel (LCIG)"],"phase":"phase_3","status":"active","brandName":"ABT-SLV187","genericName":"ABT-SLV187","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABT-SLV187 is being studied in clinical trials for the treatment of Advanced Parkinson's Disease, Parkinson's Disease, and Advanced Idiopathic Parkinson's Disease. The study involves administering ABT-SLV187 orally, in addition to comparing its effects with oral Levodopa/Carbidopa and an infusion pump.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}